Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04487-3
In an open-label extension study of the NI006-101 trial, in which patients with transthyretin amyloidosis cardiomyopathy were treated with the monoclonal antibody cliramitug, which targets misfolded transthyretin, long-term follow-up for a median of 29.3 months showed favorable safety, further reduction in cardiac amyloid burden and improvements in structural, functional and biomarker endpoints.